Key Takeaway: A recent analysis of cerebrospinal fluid (CSF) samples from a Phase 2 clinical trial indicates that CT1812 can effectively modulate α-synuclein in Alzheimer's patients. This research was presented at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference held in Lisbon, Portugal. The findings suggest promising implications for future Alzheimer's treatments.
Price reaction · baseline $1.94 (2024-03-04 close) · hit pre-market · 2 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
+8.2%
day 1
+5.2%
day 3
+1.5%
Market Sentiment Analysis
POSITIVE FACTORS
CT1812 shows potential in modulating α-synuclein.
The study contributes valuable data to Alzheimer's research.
Findings may lead to new therapeutic approaches.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Di Caro V, Pandey K, Duong D, et al. Analysis of CSF Samples from a Phase 2 Clinical Trial in Alzheimer’s Patients Show that CT1812 can Modulate α-synuclein . Poster presented at: AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference ; Lisbon, Portugal.
Frequently Asked Questions
What is CT1812?
CT1812 is a drug being studied for its potential effects on Alzheimer's disease.
What did the Phase 2 trial analyze?
The trial analyzed cerebrospinal fluid samples to assess CT1812's modulation of α-synuclein.
Where was the research presented?
The findings were presented at the AD/PD™ 2024 conference in Lisbon, Portugal.
What is α-synuclein?
α-synuclein is a protein implicated in neurodegenerative diseases like Alzheimer's.